1. Home
  2. NWSA vs IONS Comparison

NWSA vs IONS Comparison

Compare NWSA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo News Corporation

NWSA

News Corporation

HOLD

Current Price

$26.11

Market Cap

14.9B

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$79.43

Market Cap

12.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWSA
IONS
Founded
2012
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9B
12.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
NWSA
IONS
Price
$26.11
$79.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
22
Target Price
$37.34
$82.82
AVG Volume (30 Days)
3.7M
1.8M
Earning Date
02-04-2026
02-18-2026
Dividend Yield
0.76%
N/A
EPS Growth
230.83
N/A
EPS
2.06
N/A
Revenue
$8,500,000,000.00
$966,957,000.00
Revenue This Year
$5.13
$29.72
Revenue Next Year
$3.30
$0.97
P/E Ratio
$12.82
N/A
Revenue Growth
2.20
20.41
52 Week Low
$23.38
$23.95
52 Week High
$31.61
$83.61

Technical Indicators

Market Signals
Indicator
NWSA
IONS
Relative Strength Index (RSI) 49.74 52.74
Support Level $26.13 $78.52
Resistance Level $26.50 $82.09
Average True Range (ATR) 0.38 1.82
MACD 0.04 -0.32
Stochastic Oscillator 45.06 50.60

Price Performance

Historical Comparison
NWSA
IONS

About NWSA News Corporation

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: